	US 12,005,117 B2
	Methods for inhibiting fibrosis in a subject in need thereof
Nigel John Brunskill, Leicester (GB); Gregory A. Demopulos, Mercer Island, WA (US); Thomas A. Dudler, Bellevue, WA (US); and Hans-Wilhelm Schwaeble, Cambridge (GB)
Assigned to University of Leicester, Leicester (GB); and Omeros Corporation, Seattle, WA (US)
Filed by University of Leicester, Leicester (GB); and Omeros Corporation, Seattle, WA (US)
Filed on Jun. 30, 2020, as Appl. No. 16/917,157.
Application 16/917,157 is a division of application No. 15/399,524, filed on Jan. 5, 2017, granted, now 10,736,960.
Claims priority of provisional application 62/407,979, filed on Oct. 13, 2016.
Claims priority of provisional application 62/275,025, filed on Jan. 5, 2016.
Prior Publication US 2021/0077621 A1, Mar. 18, 2021
Int. Cl. A61P 13/12 (2006.01); A61K 39/395 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 39/395 (2013.01); A61P 13/12 (2018.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); A61K 2121/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

13 Claims

1. A method of protecting a kidney from renal injury in a subject that has undergone, is undergoing, or will undergo treatment with one or more nephrotoxic agents, comprising administering an amount of a MASP-2 inhibitory antibody or antigen-binding fragment thereof effective to prevent or ameliorate the incidence of drug-induced nephropathy.